City Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	14.34	13.56	2.78
Revenue Growth	-	388.19%	-
Cost of Revenue	80.36	58.42	25.68
Gross Profit	-66.02	-44.86	-22.9
Selling, General & Admin	18.44	15.06	6.19
Operating Expenses	18.44	15.06	6.19
Operating Income	-84.46	-59.92	-29.09
Interest Expense	-3.11	-2.26	-0.45
Interest & Investment Income	3.74	4.21	2.4
Other Non Operating Income (Expenses)	-2.81	-0.53	-0.7
Pretax Income	-87.67	-58.51	-27.84
Net Income	-87.67	-58.51	-27.84
Net Income to Common	-87.67	-58.51	-27.84
Net Income Growth	-	-	-
Shares Outstanding (Basic)	6	5	3
Shares Outstanding (Diluted)	6	5	3
Shares Change	-	37.97%	-
EPS (Basic)	-15.72	-12.46	-8.18
EPS (Diluted)	-15.72	-12.46	-8.18
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-80.75	-44.02	-23.93
Free Cash Flow Per Share	-14.48	-9.37	-7.03
Operating Margin	-588.90%	-441.84%	-1047.16%
Profit Margin	-611.25%	-431.39%	-1002.02%
Free Cash Flow Margin	-563.00%	-324.55%	-861.34%
EBITDA	-83	-58.75	-28.67
D&A For EBITDA	1.46	1.17	0.42
EBIT	-84.46	-59.92	-29.09

SEC Filings: 10-K · 10-Q